OS Therapies Inc
OST-HER2
osteosarcoma
Countdown
86days
FDA decision · ~ Sep 30, 2026 estimated
What's at stake
The FDA's approval decision on OST-HER2 for osteosarcoma is due ~ Sep 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 11h ago
“The Company anticipates a potential CMA decision by EMA in the fourth quarter of 2026.”